Speaker
Michael Bevilacqua, MD
CEO, CSO, DIRECTOR, & CO-FOUNDER, MACRO BIOLOGICS
Carlsbad, California, United States
Michael P. Bevilacqua, MD, PhD has 35+ years’ experience as a medical scientist, inventor, and executive.
As co-founder, CEO, and CSO of Macro Biologics (formerly known as Amicrobe, Inc.), Dr. Bevilacqua has led the development of its intellectual property, technology platform, and lead investigational products designed to prevent and treat life-threatening infections. Currently, a substantial amount of his attention focuses on corporate development and partnering efforts.
Previously, he served as Vice President of Inflammation and Chemistry at Amgen, where he built a division for development of therapeutics targeting inflammatory and immunological diseases, including IL-1 and TNF inhibitors. After Amgen, he founded Source Precision Medicine, Inc., to develop high-precision gene expression analysis for monitoring disease progression and therapeutic effectiveness, including for infectious disease.
In his academic career, Dr. Bevilacqua was a Howard Hughes investigator and faculty member of the Department of Pathology at UCSD. Prior to that, he was resident, fellow, and faculty member of the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School. There, he discovered two endothelial-leukocyte adhesion molecules and named the “Selectins”. He was chosen as a PEW scholar. He received his M.D. and Ph.D. from SUNY Downstate Medical Center, Brooklyn, New York.
As co-founder, CEO, and CSO of Macro Biologics (formerly known as Amicrobe, Inc.), Dr. Bevilacqua has led the development of its intellectual property, technology platform, and lead investigational products designed to prevent and treat life-threatening infections. Currently, a substantial amount of his attention focuses on corporate development and partnering efforts.
Previously, he served as Vice President of Inflammation and Chemistry at Amgen, where he built a division for development of therapeutics targeting inflammatory and immunological diseases, including IL-1 and TNF inhibitors. After Amgen, he founded Source Precision Medicine, Inc., to develop high-precision gene expression analysis for monitoring disease progression and therapeutic effectiveness, including for infectious disease.
In his academic career, Dr. Bevilacqua was a Howard Hughes investigator and faculty member of the Department of Pathology at UCSD. Prior to that, he was resident, fellow, and faculty member of the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School. There, he discovered two endothelial-leukocyte adhesion molecules and named the “Selectins”. He was chosen as a PEW scholar. He received his M.D. and Ph.D. from SUNY Downstate Medical Center, Brooklyn, New York.
Speaking In
3:15 PM - 3:30 PM
Wednesday, June 7
